Organisation paid for research Program year 2023 Source: CMS Open Payments

Reminton-Davis Inc

Neither a doctor nor a teaching hospital

Research payments

$338,328

47 payments

Through program year 2023, Reminton-Davis Inc is reported as receiving $338,328 in research payments, across 47 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$88,223	17
2022	Research	$230,736	23
2021	Research	$19,369	7

Breakdown

Who paid Research payments · program years 2021–2023

AbbVie, Inc. $256,910 44 payments
Abbott Laboratories $81,418 3 payments

Studies the money was for Research payments · program years 2021–2023

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo $186,701 32 payments
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study Using Venous and/or Capillary Reference $53,600 2 payments
Vitiligo is a common chronic autoimmune disease that causes the bodys immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adverse effects and change in disease activity will be assessed. $50,840 5 payments
T2 FSL2 Weight Loss $27,818 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Non-Segmental Vitiligo $19,369 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.